Table of Contents
Gcmaf is a vitamin D-binding protein. It’s scientifically called Gc protein-derived macrophage activating aspect. It’s a protein that supports the body immune system, and naturally found in the body. Gcmaf activates macrophage cells, or the cells responsible for eradicating infection and illness. (1 )
The two most recent publications on gcmaf assistance reinterpreting the biological and medical results individually observed in vitro and in vivo by a variety of researchers. The hypothesis that chondroitin sulfate may be accountable for the results so far attributed to gcmaf, resolves al the inconsistencies and contradictions that have defined this field of immunotherapy. In addition, this hypothesis lays the structure for the advancement of non-proteinic macrophage activating aspects that are not drawn out from human blood, thus avoiding all the risks connected with human blood-derived products. (2 ).
GcMAF Research study
A 1997 study tested gcmaf on mice with cancer. It discovered that gcmaf enhanced their survival from 16 days to 32 days.
A couple of years later, the researchers tested the treatment on people with breast, colorectal, and prostate cancers. They provided shots of a small quantity of gcmaf once a week. After a couple of months, all of the clients were treated, according to the research studies. Four to 7 years later on, their cancers had not return.
These results sound impressive, however there were some huge issues with the studies. For something, they were extremely small– simply eight to 16 individuals each. Everyone in the research studies had currently been on standard cancer treatments like surgery, chemotherapy, or radiation. So it was hard to inform whether these treatments, or gcmaf, caused the cancers to diminish.
Likewise, physicians usually use imaging and lab tests to phase cancers– to put it simply, to see how big the cancer is and whether it has actually spread. The researchers didn’t do this. Rather, they took blood tests to check nagalase levels, which isn’t a tested way to check for cancer or to see if it has gotten smaller.
Lastly, the researchers never ever checked whether gcmaf really activated macrophages in the patients’ blood. So they could not make certain that the treatment was working at all.
3 doctors from the Anticancer Fund, a not-for-profit group that promotes cancer research, published a letter in 2014 that detailed much of the interest in the studies. They discovered numerous errors in the studies’ claims and stated that its conclusions “make no sense.”.
Future of gcmaf
A few researchers are still investigating gcmaf as a possible cancer treatment. Some early studies suggest that it may be helpful for people with late-stage cancers. It’s difficult to know whether gcmaf works. The research studies that have actually been done so far looked at extremely small numbers of individuals. A few of them consisted of only one individual. Bigger studies are needed to show that this treatment works on cancer which it’s safe.
Macrophages might still hold promise. Scientists are attempting to find out whether monoclonal antibodies or other drugs may assist macrophages eliminate cancer cells.
Until we know more, medical professionals stay with other immunotherapies, like checkpoint inhibitors, that have more proof behind them. If you have concerns about gcmaf or any other cancer treatment you’ve checked out online, your cancer doctor is the very best individual to address them. (3 ).
Diseases for GcMAF Treatment
GcMAF macrophage activation treatment is useful in the treatment of lots of diseases, such as cancer, HIV AIDS, Liver disease B virus (HBV), Liver disease C infection (HCV), Herpes Simplex infection (HSV), Tuberculosis, Pneumonia infection, Epstein-Barr virus (EBV), cystitis/urinary system infection (UTI), Endometriosis, Selective iga shortage disorder and influenza virus.
In healthy individuals the body immune system may be able to get rid of lots of sort of illness, however people with a jeopardized immune system will gain from gcmaf therapy.
In the terrific bulk of people there are no side-effects with our second generation GcMAF therapy, or side-effects are really minor and extremely unusual. Low grade fever and eczema has actually been observed in about 1 out of 100 clients utilizing gcmaf but these were short-term results.
Treatment in our center has been by Intramuscular (IM), Subcutaneous (SC) and Intramural (IT) injection.
In Mix With Other Treatments gcmaf can be securely used with a wide variety of other standard treatments and drugs to improve their impact. We refer to this as integrative medication.
A mix with anti-cancer drugs and radiation therapy (radiotherapy) is possible. For maximum result and gain from gcmaf, administer a few days apart from chemotherapy. Radiation treatment does not have considerable results on GcMAF, so both can be utilized together at any time. In our scientific experience we have observed considerable cancer killing effects from gcmaf integrated with palliative radiotherapy in clients who went through considerable previous chemotherapy treatment.
Research studies show that gcmaf has anti-angiogenic activity in addition to tumor killing activity through the activation of macrophages.
Gcmaf can be combined with Sonodynamic Treatment (SDT), Photodynamic Therapy (PDT) or both (Sonophotodynamic Therapy, SPDT), Maitake Extract, Coley Vaccine (Coley Fluid), high-dose IV Vitamin C, low dosage Naltrexone (LDN), Alpha-Lipoic Acid, hyperthermia treatment, immunotherapies and cancer vaccines (such as autologous cancer vaccine).
Gcmaf must be utilized in mix with a minimum of 5,000 IU vitamin D3 daily. Blood levels of vitamin D are frequently low in lots of diseases such as cancer, HIV HELP, etc. Typical vitamin D levels are needed for gcmaf to work fully. Have your blood 25 hydroxy-vitamin D and calcium levels checked. If blood calcium levels end up being raised, vitamin D3 doses may need to be lowered to accomplish an optimal balance.
Combinations to Avoid GcMAF can be securely utilized with a variety of drugs and other treatments. However, we suggest:.
Very little use of steroids is preferable because of their immune suppressing result, however steroids might be securely used with gcmaf if needed and recommended by your physician.
Radiation treatment is chosen over chemotherapy whenever possible.
Treatment is by intramuscular (IM) or subcutaneous (SC) injection of the gcmaf macrophage activating element, 1-2 times weekly (or as recommended by the dealing with physician).
Treatment in our clinic has likewise been by intramural (IT) injection although IM and SC injections are without a doubt the most typical approach of administration.
Great aseptic handling with ethanol is required when using the vials. (4 ).
How does GcMAF work?
Gcmaf is a glycoprotein that triggers macrophages which in turn increases macrophage activity and transforms them into Natural Killer (NK) cells.
Gcmaf has actually been scientifically shown to be largely without any major side effects. Only flu-like symptoms in couple of percentage of those who receive the injection. (5 ).
To be more specific:
In a healthy person macrophages in our blood stream search our bodies and eliminate malignancies; they get the message to go on the attack from Gc MAF, which is transformed from Gc Protein. However deadly cells like cancer send out an enzyme called Nagalase that stops conversion of Gc protein to Gc MAF (Macrophage Triggering Aspect); so the macrophages never get the message to enter into action in this way cancer reduces the body immune system, and cancer cells grow unchecked.
To reverse this we extract Gc Protein from blood; customize it outside the body to end up being the missing out on GcMAF, and inject it once a week for 25 weeks for early cancers, 50 or more weeks for late stage cancers. (Encapsulated tumours need extra treatment.) HIV can require as little as 16 weeks.
In its role of body immune system regulator, gcmaf reverses other diseases that assault the immune system like Osteoporosis, Aids, Hodgkins, Lupus, MS, Fibromyalgia, Parkinsons, various bacterial and viral infections and numerous types of Immune dysfunction.
Small pre-clinical trials to develop the case are once again happening.
Those diagnosed with any of these illnesses or who are otherwise encouraged of the advantages of gcmaf for their health and who have done their own research study on it are welcomed to respond. We ask for a copy of diagnostic details and upgrade reports from a physician throughout and after treatments, to assist develop the case that gcmaf is a remedy for different diseases, which will help to make it available to the general public. Individuals are complimentary to stop at any time. (6 ).
An extremely relevant GcMAF history
Gcmaf first sprang to internet notoriety in 2015, with an alternate health and conspiracy publication, Natural News, claiming the following.
A specific remedy named gcmaf (brief for “Gc protein-derived macrophage triggering factor,” which is a chemically altered form of a natural protein that presumably promotes the activity of a particular sort of leukocyte) “has the prospective to be a universal cure for cancer”.
It didn’t take long for gcmaf to attain messianic status in the world of online hocus pocus and make-believe medical remedies. Natural News continued in the very same post;
” [gcmaf] is also thought,” the web site reported, “to be capable of dealing with and reversing autism, HIV, liver/kidney disease and diabetes.” Rumor has it that gcmaf has the possible to be a cure for much more diseases, such as herpes, as well.”.
Despite the many research study posts published in trustworthy medical journals (most now pulled back) claiming to confirm gcmaf as effective in the treatment of cancers, gcmaf does not treat cancer, or for that matter, any other condition. It was, and possibly still is, a drug for which there is no clear clinical evidence to recommend efficacy for anything. Hints of promise have never ever translated into actual results.
How it happened thought about by some as the cure-all for cancer, is another tale entirely, and one well worth following. In a 2017 expose by Snopes, capably assisted by the Anticancer Fund (ACF), gcmaf was finally exposed. In the short article, its creator and primary supporter, Dr. Nobuto Yamamoto. Was shown to be guilty of falsifying scientific trials in a concerted decades-long effort to offer the lie of gcmaf.
The seriousness and implications of Yamamoto’s scams have extensive ramifications for the medical community, its publications, and the procedures it depends upon to verify brand-new medications. It has highlighted how a once-respected member of the medical neighborhood can go rogue, utilizing the system’s “fail-safes” versus it. The gcmaf saga should not be forgotten. It works as a long-term suggestion of unaddressed industry loopholes, most of which stay in place.
The result of publishers not getting rid of problematic research study leads to yet more documents, based upon the theories promoted in the initial disproven research study. Here is a classic example, where 2 of Yamamoto’s documents on gcmaf have been referenced by researchers, in a recent paper entitled “Possible function of gcmaf in reducing the intensity of COVID-19-induced immune actions: Lesson learned from HIV”.
2 concerns to the publications involved. Why have you refused to pull back Yamamoto’s erroneous papers and where is the peer review procedure that would recognize the research in the paper referenced above to be flawed? Allowing erroneous and problematic research studies to persist endangers the public.
You can discover the complete Snopes Short article here. Entitled, “How a Retired Researcher’s Questionable ‘Institute’ Convinced the Internet That Cancer Was Cured”, it produces interesting reading and we advise it as a case study in professionally committed pharmaceutical deceptiveness. Yamamoto had actually delighted in a long and prominent career till gcmaf, making the motivation for the fraud that much more difficult to determine, and professionals stay divided on his real inspiration.
In November of 2009, Yamamoto effectively offered his patents for gcmaf and associated intellectual property to an Israeli biopharmaceutical business, Efranat Macrophage. The business, after initially embracing Yamamoto, slowly distanced itself from him, rebranding gcmaf as EFF-022 and going as far as altering the drug’s name mid-trial.
While the medical neighborhood slowly turned their backs on gcmaf, the alternate health and conspiracy areas of the web were far from made with their brand-new beloved, having actually seen the marketing and sales potential for this brand-new “wonder” cure. (7 )
” Cancer cured for good?”– GcMAF and the wonder treatment
As an organisation dedicated to beating cancer, we have a deep-rooted interest in any new research advancements that might lead to brand-new, more effective treatments for the illness.
So when we received an enquiry from a supporter about an article entitled “Cancer treated for good” by Costs Sardi and Timothy Hubbell * we were intrigued. The post discuss research study by Nobuto Yamamoto in the United States, taking a look at a protein called GcMAF (aka gcmaf). His published research studies appear to show that injections of very small amounts of GcMAF can “treat” people with breast, bowel and prostate cancer.
According to the article, “It works 100% of the time to eliminate cancer totally, and cancer does not repeat even years later on.” Could this be the so-called ‘cure for cancer’ that we’ve been looking for all these years?
Sadly– similar to a lot of things in life– if it sounds too great to be true it probably is. Significant concerns are now being raised about GcMAF (for example, this investigation by the BBC) and the companies that offer it, and it is not certified in the UK to deal with any disease.
Let’s explore a bit more.
What’s the concept behind it?
Dr Yamamoto studies the body immune system– the extremely complicated network of cells that helps to keep us healthy. The cells of the immune system– white blood cells– fight bacterial and viral infections since they can acknowledge and attack these ‘foreign’ invaders. However they’re not so proficient at tackling cancer, given that tumours grow from our own cells and have smart mechanisms to ‘mask’ them from immune attack.
Macrophages (significance “big eaters” in Greek) are an essential kind of white blood cell. They patrol the body, consuming foreign invaders and dead cells. They also help to notify other immune cells to the existence of infections.
Macrophages can be stirred into action by a little sugar-coated protein (glycoprotein) called GcMAF, short for Gc Macrophage Triggering Factor, which is produced by the body. However it’s believed that the production of GcMAF is blocked by an enzyme called Nagalase (alpha-N-acetylgalactosaminidase), produced by lots of cancers. This is among the systems that assists tumours avert the body immune system.
Yamamoto’s theory is that injecting cancer clients with GcMAF ought to activate their macrophages to fight the cancer. He tested it back in 1997 in a paper published in the journal Cancer Research, showing that injecting GcMAF into mice transplanted with cancer cells could improve their survival from around 16 days to around 35.
However the treatment did not ‘cure’ the cancer, as the cancer cells continued to increase, eventually killing the animals.
Nevertheless, there are concerns about the science underpinning the idea that GcMAF can deal with cancer. For instance, other researchers have found no distinctions in the levels of GcMAF in between cancer patients and healthy people– and the levels they do discover are far higher than the extremely little doses proposed to work by Yamamoto. It’s hard to see exactly how this finding fits with the concept of how the treatment is expected to work, and it doesn’t support making use of GcMAF as a treatment for cancer.
Fast-forward a few years, to the publication of 3 documents detailing the outcomes of scientific trials of GcMAF performed by Yamamoto, checking the treatment on patients with breast, bowel and prostate cancer.
Keep in mind: The breast cancer paper has now been pulled back, due to different worry about the work. Read more on the retractionwatch blog site. The bowel cancer paper has actually also now been retracted. This letter information a few of the issues about the work.
The outcomes seem surprising– all the clients on the trials are ‘treated’ of cancer. Certainly this is an amazing development?
Put bluntly, no it isn’t. There are substantial clinical problems with the trials. For a start, all the studies are extremely small, including less than twenty clients in each– rather than the thousands needed to make the sort of claims mentioned above.
Next, all the patients involved had actually gotten basic treatment for their cancer, including surgery, chemotherapy and/or radiotherapy. This is a somewhat unconventional design for a trial of this kind, since it makes it very hard to tell if any successes are due to the new drug, or the more standard treatments.
On top of this, the researchers didn’t actually monitor the progress of tumours in the clients, and offer no clinical info about them. Instead they opt to measure levels of Nagalase in the blood, rather than taking a look at any standard established markers for cancer.
For example, in the case of the breast cancer clients, there is no detail about their “TNM” (tumour, node, transition) status. This is a basic step of how far a client’s cancer has spread out, and is utilized to calculate the probability that it will return.
In addition, the researchers didn’t do any tests to show that injected GcMAF was actually activating macrophages in the clients’ blood, or even operating in the way that they anticipate. There is no info about levels of cytokines– the proteins produced by immune cells when they are activated– or analysis of the clients’ immune cells.
Possibly most significantly, there are no controls– neglected patients for comparison– and the studies just followed the clients for a couple of years. We have no chance of telling whether their cancers were growing again, or had actually been successfully dealt with, and whether this was because of GcMAF or the other treatment they had actually gotten.
Considered that 80 percent of all females with breast cancer make it through for a minimum of 5 years, an unrestrained study revealing that 16 ladies of unidentified TNM status survive for at least 4 years is no terrific shakes, clinically speaking.
Another little research study of 20 clients with a range of cancers, published in 2013, has comparable issues. It’s not a regulated trial, and the scientists just measure nagalase levels as an indication of whether the treatment is ‘working’, and provide really little hard clinical information (such as scans or other identified tests) about the patients’ real tumours. For instance, in one concerning case, although the researchers showed that an ovarian cancer patient’s nagalase levels had actually decreased, the levels of another marker– CA125, which is produced by ovarian cancer cells– had gone up. Yet this is classed as an “improvement” in the paper, with no other supporting details. Overall, this research study is likewise a long way from being convincing evidence that the treatment works.
Another informing point is the type of journal in which the research was released. If this research study was genuinely groundbreaking, and pointed the way to a cure for cancer, then the research would likely be discovered in top-tier ‘high-impact’ medical journals like The Lancet, The New England Journal of Medicine or the Journal of the American Medical Association.
And lastly, virtually all the recommendations in the papers are to other papers published by Yamamoto and his team. If GcMAF was indeed a promising prospect for a successful cancer treatment, you ‘d expect lots of other research study to reveal the very same thing. Scientists are normally fast to spot appealing, emerging fields of research and follow suit.
The poor quality of scientific documents supporting gcmaf is discussed here on the Scholarly Open Access blog site.
Is there hope?
Although this particular method isn’t all it’s hyped up to be, harnessing the power of immune system could be an extremely powerful method to treat cancer.
And lots of Cancer Research study UK-funded scientists are also operating in this field. For instance, Teacher Fran Balkwill and her group are working on ways to trick macrophages and other immune cells into assaulting cancer cells.
In 2014, researchers in Israel started a small early-stage scientific trial taking a look at the dosage and security of gcmaf in cancer patients. (8 ).
Dr Yamamoto specifies gcmaf does not have side effects. Our experiences concur: gcmaf has actually revealed no side effects of its own. That’s not unexpected– your body expects to have it.
However your rebuilt immune system might sometimes offer you minor negative effects, however larger adverse effects with late phases of cancer, and occasionally serious impacts with autism, HIV and ME/CFS, as infections fight back versus the reconstructed immune system’s attack.
People’s responses to a rebuilt immune system are really various– from absolutely no, which is normal, to severe in a minority of cases.
Inside 2 hours gcmaf will start to impact your immune system, and (if your immune system is at least partially active) a shot of 0.1 ml or more may cause exhaustion which normally lasts 3-4 hours. You may feel better than usual for the first 2-3 weeks as the body immune system gets up.
Gcmaf is a protein that your body ought to have made by itself, and there is a small chance (under 0.1%) you might have an allergy, usually within the very first 2 hours. If in doubt start with a 0.05 ml dosage, then 0.1 after 12 hours. If you do have a reaction, it can be treated with anti-histamine tablets, which can normally be bought from a chemist without prescription (hay fever is an allergy).
We have actually seen favorable, however not yet unfavorable autoimmune responses.
Other minor side effects might consist of cytokine activity (with accompanying fatigue and minor weight loss, no such reports yet), histamine release (with potentially a headache) and the symptoms of a fever (3.5 hours of hot flushes) as the body immune system goes to work.
Many never discover anything more than an improving sense of well being. (9 ).
Other crucial points
Triggering macrophages with High Dosage GcMAF is a vital part of any treatment program which can be used alone or in mix with the majority of other therapies.
GcMAF works particularly well in synergy with targeted therapies which don’t damage the body immune system. Examples of targeted treatments include hormonal agent therapies, monoclonal antibody drugs, small-molecule drugs, signal transduction inhibitors (HER2 inhibitors, BRAF inhibitors, EGFR inhibitors), angiogenesis inhibitors, immunotherapy drugs (such as drugs that target CTLA-4 protein).
Second Generation GcMAF has the advantage of having no adverse effects so treatment must be continued as long as necessary while illness exists. This is a substantial advantage over many standard therapies which have cumulative toxicity that restricts their use.
GcMAF never stops working and will continue to activate macrophages while treatment is continued, either by GcMAF injections and/or oral administration of Colostrum GcMAF. (10 ).